Alzamend Neuro, Inc. 8-K

What Happened

• Alzamend Neuro, Inc. (ticker: ALZN) announced in an 8-K that on March 20, 2026 it received a letter from Nasdaq’s Listing Qualifications staff notifying the company that its reported stockholders’ equity of approximately $2.2 million (as of January 31, 2026, per its Form 10-Q) does not meet the Nasdaq Capital Market minimum requirement of $2.5 million under Listing Rule 5550(b)(1).
• The notice does not affect current trading; ALZN will continue to trade on Nasdaq while the company works to regain compliance.

Key Details

• Date of Nasdaq notice: March 20, 2026.
• Reported stockholders’ equity: ~ $2.2 million (as of Jan 31, 2026) vs. Nasdaq minimum requirement of $2.5 million.
• Compliance timeline: 45 days to submit a plan (deadline May 4, 2026); if Nasdaq accepts the plan, the company may be given up to 180 days from the notice (until Sept 16, 2026) to evidence compliance.
• If Nasdaq rejects the plan or the company fails to regain compliance, Nasdaq could begin delisting proceedings; the company may appeal to a Nasdaq Hearings Panel, which would stay delisting pending the hearing.

Why It Matters

• This is a material regulatory compliance issue: failing to meet Nasdaq’s minimum equity requirement could lead to delisting if not cured. Continued listing depends on Nasdaq accepting a remediation plan and on the company’s ability to increase stockholders’ equity or otherwise satisfy listing standards.
• For investors, the filing highlights operational and financial risks cited by the company (ongoing losses, negative cash flow, need for additional funding, and limited revenue from its Bitnile.com platform). There is no guarantee the company can secure the relief or financing needed to regain compliance.